Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models

Recent development of checkpoint inhibitors has shed light on non-small-cell lung cancer (NSCLC) patients without targetable alterations. The excitement about using immunotherapy to treat NSCLC has been driven by results from clinical studies evaluating antibodies to programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) [1]. A strategy targeting immune checkpoints such as PD-1/PD-L1 showed promising clinical benefits and introduced a paradigm shift in treatment by showing significantly improved progression-free survival and overall survival compared to conventional platinum-based chemotherapy in NSCLC [2,3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research